Immunogen | IMGN - Прибыль до налогообложения



Прибыль до налогообложения Изменить Дата
AbbVie USD 7.87B 253M 2026-09
Agios Pharmaceuticals USD -65.04M 35.66M 2026-09
Amgen USD 4.19B 1.42B 2026-09
Astellas Pharma JPY 186.51B 138.49B 2026-06
AstraZeneca USD 5.49B 684.4M 2026-09
Bristol-Myers Squibb USD 4.99B 1.75B 2026-06
Eli Lilly USD 8.79B 457M 2026-09
Exelixis USD 282.78M 20.11M 2026-09
Halozyme Therapeutics USD 284.9M 104.57M 2026-06
Heron Therapeutics USD -2.95M 14.54M 2025-12
Intrexon USD -60.48M 27.09M 2024-06
Karyopharm Therapeutics USD -22.39M 17.51M 2026-03
MacroGenics USD -69.64M 32.87M 2026-06
Nektar Therapeutics USD -43.09M 8.39M 2026-03
Novartis USD 1.32B 2.52B 2026-09
Pfizer USD 3.38B 4.04B 2026-09
Regeneron Pharmaceuticals USD 1.53B 696.6M 2026-06
Roche Holding CHF 11.17B 6.38B 2026-06
Sanofi EUR 6.07B 5.23B 2026-09